OnKure Therapeutics, Inc. (NASDAQ:OKUR) — Market Cap & Net Worth
Market Cap & Net Worth: OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. (NASDAQ:OKUR) has a market capitalization of $32.79 Million ($32.79 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23386 globally and #5034 in its home market, demonstrating a -9.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OnKure Therapeutics, Inc.'s stock price $3.82 by its total outstanding shares 12861672 (12.86 Million). See OnKure Therapeutics, Inc. capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
OnKure Therapeutics, Inc. Market Cap History: 2021 to 2026
OnKure Therapeutics, Inc.'s market capitalization history from 2021 to 2026. Data shows change from $1.10 Billion to $49.13 Million (-49.87% CAGR).
Index Memberships
OnKure Therapeutics, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #666 of 976 |
Weight: OnKure Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OnKure Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OnKure Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OKUR by Market Capitalization
Companies near OnKure Therapeutics, Inc. in the global market cap rankings as of August 3, 2026.
Key companies related to OnKure Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
OnKure Therapeutics, Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, OnKure Therapeutics, Inc.'s market cap moved from $1.10 Billion to $ 49.13 Million, with a yearly change of -49.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $49.13 Million | +31.72% |
| 2025 | $37.30 Million | -66.28% |
| 2024 | $110.61 Million | -46.25% |
| 2023 | $205.79 Million | -31.33% |
| 2022 | $299.68 Million | -72.75% |
| 2021 | $1.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of OnKure Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.79 Million USD |
| MoneyControl | $32.79 Million USD |
| MarketWatch | $32.79 Million USD |
| marketcap.company | $32.79 Million USD |
| Reuters | $32.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, includin… Read more